In a recent report, gain of ≤ 10% body weight was observed in six out of seven rheumatoid arthritis patients treated with baricitinib but not with tofacitinib, a JAK1/3 inhibitor [18]. The gene discussed is JAK1; the disease is rheumatoid arthritis.